Result for
Topic: Testing and Treatment
April 20, 2021
Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York
No difference in ventilator-free days through 28 days (p=0.86) was observed between patients randomized to receive convalescent plasma (CP) vs standard plasma in a 4:1 randomized doubled-blind placebo-controlled trial (n=74). CP increased antibody levels by 14%, whereas standard plasma led to a 7% decrease. All-cause mortality through 90 days was non-significantly lower in the CP…
April 19, 2021
Impact of Convalescent Plasma Therapy on SARS CoV-2 Antibody Profile in COVID-19 Patients
Convalescent plasma (CP) treatment did not predict survival in a longitudinal analysis of plasma samples from hospitalized patients with COVID-19 (n = 16) treated with either CP or standard of care. Among 8 patients who died, marked declines in neutralization titers were observed prior to death, which CP treatment did not reverse. Irrespective of CP…
Randomized Comparative Clinical Trial to Evaluate Efficacy and Safety of PNB001 in Moderate COVID-19 Patients
[Pre-print, not peer-reviewed] Patients with moderate COVID-19 (n=40) randomized to treatment with the novel anti-inflammatory medication PNB001 had lower clinical severity scores assessed by the 8-point WHO Ordinal Scale for COVID-19 at day 14 than patients who received standard of care alone (score 0.2 vs. 1.1, p<0.05). The multicenter randomized trial did not detect a…
April 15, 2021
Role of Interferon Therapy in Severe COVID-19: The COVIFERON Randomized Controlled Trial
The interferon therapy IFNβ1a was associated with a shorter time to clinical improvement (TTCI) compared to control (HR: 2.4, 95% CI 1.1-5.2) among people with severe COVID-19 in a 1:1:1 randomized, placebo-controlled, open-label trial (n=60), but patients treated with IFNβ1b did not have a statistically significant different TTCI (HR: 1.4, 95% CI 0.6-3.2). The median…
April 14, 2021
Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study
Adults with COVID-19 who were not hospitalized and received the monoclonal antibody therapy bamlanivimab (n = 218) had a 63% lower 30-day hospitalization rate than those who did not receive the treatment (n = 185) in a case-control study conducted between November 20, 2020 and January 19, 2021. Odds of hospitalization was 4.2 times higher…
April 13, 2021
Inhaled Budesonide for COVID-19 in People at Higher Risk of Adverse Outcomes in the Community Interim Analyses from the PRINCIPLE Trial
[Pre-print, not peer-reviewed] The inhaled corticosteroid budesonide reduced time to recovery among older ambulatory SARS-CoV-2-infected adults by 3 days, according to an interim analysis of a randomized, open-label trial (PRINCIPLE Trial). In participants either 65 years and older without co-morbidities or less than 50 years with co-morbidities given 14 days of 800 mcg of budesonide…
Inhaled Budesonide in the Treatment of Early COVID-19 (STOIC): A Phase 2, Open-Label, Randomised Controlled Trial
Treatment with the inhaled corticosteroid budesonide within 7 days of onset of mild COVID-19 symptoms was associated with a 91% reduction in risk of an urgent care visit, an emergency department consultation, or hospitalization. In the per-protocol analysis of the randomized, open-label phase 2 trial, one of these three outcomes occurred in 14% (10 of…
April 12, 2021
Real-World Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States
[Pre-print, not peer-reviewed] Monoclonal antibody treatment significantly reduced the risk of subsequent emergency department visit or hospitalization among patients with COVID-19 (n = 598) in a real-world study using electronic health record data. Among 270 (45%) patients treated with the monoclonal antibody bamlanivimab, 5 (1.9%) presented to the emergency department (ED) or required hospitalization within…
Neutralization of SARS-CoV-2 Variants by Convalescent and Vaccinated Serum
[Pre-print, not peer-reviewed] Sera from convalescent individuals (n = 44) and individuals who received the Pfizer-BioNTech vaccine (n = 51) showed reduced neutralization activity against the SARS-CoV-2 B.1.1.7 and B.1.351 variants. Among vaccinated individuals, the geometric mean 50% receptor binding domain (RBD) antibody concentration was 1.3-fold lower for the B.1.1.7 variant and 1.4-fold lower for…
April 9, 2021
COVID-19 Stats: College and University COVID-19 Student Testing Protocols, by Mode of Instruction (N = 1,849) — United States, Spring 2021
As of March 17, 2021, a total of 899 (49%) of 1,849 public and private nonprofit 4-year U.S. colleges and universities provided some type of COVID-19 testing for asymptomatic students. A total of 548 (30%) institutions conducted classes in-person or in a hybrid format. At 389 (43%) institutions there were protocols that required periodic testing…
Previous page Next page